Prostate cancer is one of the hardest cancers to treat with immunotherapy, a treatment that uses the body's own immune system to fight cancer. However, a new study suggests that this could soon change.
Researchers have developed an experimental RNA-based technology that helps the immune system find and attack prostate cancer cells more effectively.
The study, published in Nature Biomedical Engineering, found that the new approach made prostate tumours easier for immune cells to recognise in laboratory mice.
The researchers believe the technology could one day improve treatment for prostate cancer and other cancers that do not respond well to immunotherapy.
Prostate cancer is a major health problem around the world. According to global estimates, it is the second most common cancer among men, with more than 1.5 million new cases diagnosed every year.
In Kenya, it is the leading cancer among men and the third most common cancer overall, with about 3,601 new cases reported each year, accounting for 10 per cent of all cancer cases in the country.
Immunotherapy has transformed the treatment of several cancers, including melanoma and some types of lung cancer.
Instead of attacking cancer directly with drugs, the treatment helps the body's immune system identify and destroy cancer cells.
Unfortunately, immunotherapy has not worked well against prostate cancer. Scientists say this is because most prostate tumours are known as "immune cold." This means they attract very few T cells, which are the white blood cells that search for and destroy infected or cancerous cells.
Without enough T cells reaching the tumour, the immune system cannot mount a strong attack, making immunotherapy much less effective.
To understand why this happens, researchers looked closely at messenger RNA, or mRNA. This is the molecule that carries instructions from DNA and tells cells which proteins to make. In prostate cancer cells, they found that some of these RNA molecules become shorter than normal.
These shorter RNA molecules allow cancer cells to produce large amounts of a protein called SPSB1. This protein removes an important marker known as the MHC-1 complex from the surface of cancer cells.
The MHC-1 complex acts like an identification badge. It helps T cells recognise which cells are dangerous. When the marker disappears, the cancer cells become almost invisible to the immune system.
The researchers developed a new CRISPR-based tool to solve this problem. Unlike traditional CRISPR technology, which cuts DNA, this new tool works only on RNA. It restores the shortened RNA to its normal length instead of changing a person's genes.
When the RNA returned to its normal length, the cancer cells produced less of the harmful SPSB1 protein. As a result, the MHC-1 marker returned to the surface of the cancer cells, making them easier for T cells to find.
The researchers then combined the RNA treatment with immunotherapy. They found that many more immune cells entered the tumours and destroyed cancer cells. Tumours in the mice responded much better to treatment than those that received immunotherapy alone.
The researchers also checked whether the new technology caused unwanted changes in other parts of the cells. They found no evidence of major side effects in their laboratory studies, although they say much more testing is needed.
"The findings show that making prostate cancer cells easier for the immune system to see could greatly improve the success of immunotherapy."
Although the results are encouraging, the treatment is still in the early stages of research. So far, it has only been tested in mice.
Human clinical trials will be needed before doctors know whether the technology is safe and effective for patients.
The researchers believe the same approach may also work against other immune-cold cancers, including pancreatic cancer, which is also difficult to treat with immunotherapy.
Cancer experts say the study is important because it targets one of the biggest challenges in cancer treatment: helping the immune system recognise tumours that have learned how to hide.
They also say RNA-based medicine is becoming an exciting area of research. Unlike treatments that permanently change DNA, RNA therapies work on temporary genetic messages inside cells. This could reduce the risk of long-term side effects while still improving treatment.
"If future studies confirm these results in people, this technology could provide a new way to treat prostate cancer and other cancers that have not responded well to current immunotherapy."
The researchers caution that patients should not expect the treatment to become available soon. More laboratory studies and clinical trials are needed to confirm its safety and effectiveness.
The findings offer new hope. By helping the immune system recognise tumours that were previously hidden, the technology could lead to more effective cancer treatments and better outcomes for thousands of men diagnosed with prostate cancer each year.
Comments
Sign in with Google to comment, reply, and like comments.
Continue with Google